NCT00111982

Brief Summary

The purpose of this study is to determine long-term efficacy of continuous IPu liatermin infusion administered with concomitant standard anti-Parkinsonian therapy.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Dec 2003

Typical duration for phase_1

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2003

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

May 27, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 30, 2005

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2005

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2006

Completed
Last Updated

February 26, 2010

Status Verified

February 1, 2010

Enrollment Period

1.9 years

First QC Date

May 27, 2005

Last Update Submit

February 25, 2010

Conditions

Keywords

bilateral, idiopathic Parkinson's Disease

Outcome Measures

Primary Outcomes (1)

  • Percent change in UPDRS

    24 months

Secondary Outcomes (1)

  • Incidence of treatment emergent and device related adverse events

    24 months

Study Arms (1)

Liatermin

EXPERIMENTAL

Bilateral continuous infusion of liatermin for up to 24 months.

Biological: Liatermin

Interventions

LiaterminBIOLOGICAL

Liatermin

Liatermin

Eligibility Criteria

Age35 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

Parkinson Disease

Interventions

Glial Cell Line-Derived Neurotrophic Factor

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Glial Cell Line-Derived Neurotrophic FactorsNerve Growth FactorsIntercellular Signaling Peptides and ProteinsPeptidesAmino Acids, Peptides, and ProteinsProteinsNerve Tissue ProteinsBiological Factors

Study Officials

  • MD

    Amgen

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 27, 2005

First Posted

May 30, 2005

Study Start

December 1, 2003

Primary Completion

November 1, 2005

Study Completion

February 1, 2006

Last Updated

February 26, 2010

Record last verified: 2010-02